[Posology of drugs in the obese patient]

[Posology of drugs in the obese patient] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Posology of drugs in the obese patient] Abstract Text:

J Biollaz,J L Schelling,

[Posology of drugs in the obese patient] Publishing Authors By Initials

J Biollaz,JL Schelling,

For similar biochemical phenomena, metabolism, and nutrition: metabolism: pharmacokinetics research abstracts see: biochemical phenomena, metabolism, and nutrition: metabolism: pharmacokinetics research

PUBMED ID PMID:

MEDLINE DATE:

[Posology of drugs in the obese patient] Journal Published:

PUBLICATION TYPE: Review

Journal: Therapeutische Umschau. Revue thérapeutique

VOLUME: 44

Page Numbers: 601-6

Journal Abbreviation:

ISSN: 0040-5930

DAY: 12

MONTH: Aug

YEAR: 1987

[Posology of drugs in the obese patient] Information

Number of References: 13

LANGUAGE: fre

NlmUniqueID: 407224

[Posology of drugs in the obese patient] Keywords Mesh Terms:

KEYWORDS: Pharmacokinetics

MESH TERMS: administration & dosage

Chemical & Substance for Abstract: [Posology of drugs in the obese patient] Information

Substance Name: Pharmaceutical Preparations

Registry Number: 0

Grant and Affiliation Information for [Posology of drugs in the obese patient]

AFFILIATION:

Country: SWITZERLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ther Umsch

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Posology of drugs in the obese patient Related Publications

• A new animal model for maxillary sinus floor augmentation: evaluation parameters.
• Daptomycin, a lipopeptide antibiotic in clinical practice.
• Does renal failure induce a decrease in cyclosporine blood concentrations?
• Juvenile hormone action to suppress gene transcription and influence message stability.
• Pitfalls in measuring the endocannabinoid 2-arachidonoyl glycerol in biological samples.
• Post-traumatic stress disorder in somatic disease: lessons from critically ill patients.
• Risk factors for development and progression of diabetic kidney disease and treatment patterns among diabetic siblings of patients with diabetic kidney disease.
• Standards for adequate minimum personal health services.
• The NHE1 Na+/H+ exchanger regulates cell survival by activating and targeting ezrin to specific plasma membrane domains.
• The intrinsic brain iso-renin--angiotensin system in the rat: its possible role in central mechanisms of blood pressure regulation.
• [Advantages and disadvantages of drug combinations in cardiovascular therapy]
• [Drug treatment of cerebral disorders in senility]
• [Medicamentous dyspnea (author's transl)]
• [Medications and modern medicine]
• [Posology of drugs in the obese patient]
• [Simulation and prevention of a positive urine sugar reaction by the presence of large quantities of ascorbic acid (vitamin C). Critical study of a source of error in routine testing for glucose in the urine.]
• [Surveys on side effects of drugs]
• [Undesirable neuropsychological and muscular effects]
• [Which drugs should not be prescribed in pregnancy]